AUTHOR=Wang Zhihong , Zeng Tianmei , Li Yong , Zhang Ding , Yuan Zhengang , Huang Mengli , Yang Yuan , Zhou Weiping 

TITLE=PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature

JOURNAL=Frontiers in Immunology

VOLUME=Volume 12 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.799822

DOI=10.3389/fimmu.2021.799822

ISSN=1664-3224

ABSTRACT=Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with a poor prognosis. Gemcitabine plus cisplatin as first-line standard of care brings an overall survival of approximately 12 months. Immunotherapy strategy represented by programmed cell death 1 (PD-1) inhibitors has been applied to the systemic treatment of advanced advanced iCCA. However, immunotherapy combined with chemotherapy as a first-line maintenance therapy were rare reported. In our report, we presented an advanced iCCA patient with a dramatic response to now over 16 months of a PD-1 inhibitor (sintilimab) combined with gemcitabine plus cisplatin as the first-line therapy and sintilimab combined with capecitabine as a maintenance therapy.